Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

shankar besta

  • Home
  • Author: shankar besta

APAC automotive hybrid EV powertrains market to expand at 5.9% CAGR over 2024-29, forecasts GlobalData

As consumers grow more environmentally conscious, they are recognizing hybrid vehicles as a practical and affordable alternative to internal combustion engine (ICE) cars and battery electric vehicles (BEVs). The Asia-Pacific (APAC) region, with China, Japan, and India at the forefront, leads the global market in the adoption of hybrid vehicles. Governmental efforts to promote zero-emission […]
Read more

GLP-1R market: A two horse race, says GlobalData

The popularity of glucagon-like peptide-1 receptor (GLP-1R) drugs has exploded in recent years due to their abilities in effectively treating metabolic-related disorders such as obesity and type 2 diabetes. As obesity rates rise and trust in GLP-1R products grows, sales for drugs targeting this receptor are forecast to increase fourfold to an estimated $142 billion […]
Read more

APAC automotive tyres and wheels market to expand at 1.7% CAGR over 2024-29, forecasts GlobalData

Due to the increasing number of vehicles produced, constant technological advancements and innovations,  the market volume for tyres and wheels has grown significantly over the years. However, as the innovations made tyres sturdier and reduced the occurrence of flat tyre scenarios, the demand for spare wheels has decreased, negatively impacting the sector and lowering the […]
Read more

Innovation surge in lipid nanoparticle technology to reshape gene therapy landscape, reveals GlobalData’s Technology Foresights

Intellia Therapeutics unveiled promising proof-of-concept data for its proprietary lipid nanoparticle (LNP) delivery platform in July this year. This development marks a significant milestone in the emergence of LNPs as a crucial non-viral vector for gene therapy delivery. The success paves the way for trials targeting various new applications of LNP technology, which could reshape […]
Read more

2024 UEFA European Championships generates estimated sponsorship revenue of $535.25 million, reveals GlobalData

The 2024 edition of the UEFA European Championships saw sponsorship deals from a total of 25 brands, with the largest deal in terms of annual value being with adidas. Alongside Sportradar, Coca-Cola’s deal ranks joint second in terms of the largest sponsorship deals. Overall, the 2024 UEFA European Championships generated sponsorship revenue of $535.25 million, […]
Read more

APAC automotive keyless entry system market to decline at 0.5% CAGR over 2024-29, forecasts GlobalData

Consumer preference has increasingly favored keyless entry systems, encompassing both active and passive variants, in the Asia-Pacific (APAC) region. This trend is propelled by the convenience of vehicle access and the enhanced aesthetic appeal these systems provide. Despite these positive aspects, there is a palpable concern among consumers, fueled by numerous incidents of theft involving […]
Read more

Abbott partnership could improve Medtronic’s faltering diabetes care segment, says GlobalData

Medtronic and Abbott Laboratories recently announced a partnership to integrate the former’s automated insulin delivery (AID) systems, such as the MiniMed insulin pump, with Abbott’s continuous glucose monitor (CGM) technology. This partnership is Medtronic’s first with another major diabetes care company and follows disappointing results from its diabetes care division since 2022.  To be developed […]
Read more

Abbott shakes up dual chamber leadless pacemaker space with AVEIR DR system, says GlobalData

Abbott Laboratories’ AVEIR DR dual chamber leadless pacemaker system incorporates several cutting-edge technologies that not only improve patient outcomes but also sets a new standard in the management of heart rhythm disorders. Since receiving FDA approval in July 2023, Abbott has acquired approximately 30-40% of share from Medtronic in the dual chamber leadless pacemaker space, […]
Read more

Scholar Rock’s apitegromab holds potential to become first myostatin inhibitor for SMA patients, says GlobalData

As part of its Q2 2024 Financial Results and Business Progress reporting, Scholar Rock disclosed new positive data from its Phase II TOPAZ trial, with results showing continued and sustained motor function over four years in non-ambulatory patients with spinal muscular atrophy (SMA) treated with apitegromab and nusinersen. The positive data lays the foundation for […]
Read more
1 … 66 67 68 69 70 … 136